YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis

Imai, Yasutomo; Tsuda, Tatsuya; Aochi, Seiko; Futatsugi-Yumikura, Shizue; Sakaguchi, Yoshiko; Nakagawa, Noboru; Iwatsuki, Keiji; Yamanishi, Kiyofumi

doi:10.1016/j.jdermsci.2011.06.012

Cited by 25 publications

(32 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…YKL-40 levels were found to be elevated in both psoriasis groups. On the other hand, that study showed that the YKL-40 levels of plaque psoriatic cases were significantly higher than healthy subjects [13]. Jensen et al also reported elevated serum YKL-40 levels in 48 plaque psoriasis and 42 psoriatic arthritis patients [14].…”

Section: Discussionmentioning

confidence: 89%

“…Jensen et al also reported elevated serum YKL-40 levels in 48 plaque psoriasis and 42 psoriatic arthritis patients [14]. However, the findings of these studies could not justify the cause of the elevation of this marker, which might be due to inflammation of the disease, endothelial damage, or the cardiovascular risk factors of the patient such as obesity and smoking [13,24]. In the present study, similar to recently published data, plasma YKL-40 levels were found to be elevated in cases with plaque psoriasis without any risk of ED when compared with healthy controls.…”

Section: Discussionmentioning

confidence: 94%

“…Some studies have shown that this marker regulates vascular endothelial growth factor and that it is correlated with disease activity in the spectrum of cardiovascular diseases from ED to atherosclerosis. YKL-40 has also recently been suggested as a biomarker for psoriasis and psoriatic arthritis, considering the reports of elevated levels in conditions with inflammation, such as rheumatoid arthritis [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?

et al. 2014

View full text Add to dashboard Cite

Psoriasis is a disease that can contribute to a risk of atherosclerosis. In several studies, impaired endothelial dysfunction (ED) is correlated with psoriasis. Serum YKL-40 is a new inflammatory biomarker of vascular damage, like ED and cardiovascular diseases. The aim of the study was to compare relevance of serum YKL-40 levels in psoriasis patients and healthy subjects according to ED diagnosis and identifiable cardiovascular risk factors. Sixty (31 female, 29 male) patients with plaque psoriasis, and 30 (18 female, 12 male) healthy controls were selected according to whether they had at least one or no identifiable risk factors for cardiovascular disease. All subjects were evaluated ultrasonographically for endothelial function and diagnosed as with or without ED and all groups compared for serum YKL-40 levels. YKL-40 levels of psoriatic patients with ED were higher than healthy controls with ED (P = <0.05). There were no statistical differences in between subjects without ED. YKL-40 levels of patients over age of 40 were higher than younger ones (P < 0.05). But in healthy controls, there were no differences. In comparison of cardiovascular risk-positive (RP) patients and RP healthy subjects, YKL-40 levels were higher in RP patients (P = <0.05). The elevation of plasma YKL-40 in psoriasis can be associated not only with inflammation of the disease, but also with ED. YKL-40 can be used as a marker for predicting and preventing cardiovascular diseases in RP psoriatic patients with age above 40.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Recent reports show the PDPN expression in normal skin components and diseased skin conditions such as psoriatic epidermis. 1 While the STAT-3-dependent pathway is involved in both PDPN expression 1 and the pathomechanism of psoriasis, 2 a detailed analysis of PDPN expression depending on the proliferative phase of psoriatic epidermis has not been fully elucidated. Psoriatic epidermis has been classified into typical granular layer (GL)-negative markedly hyperproliferative epidermis and GL-positive stationary and/or healing epidermis.…”

Section: Podoplanin Expression Is Inversely Correlated With Granular mentioning

confidence: 99%

YKL‐40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis

Imai

Aochi

Iwatsuki

et al. 2013

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

“…YKL‐40 has diverse roles in cell proliferation, differentiation, survival, inflammation and tissue remodeling, and its aberrant expression is associated with the pathogenesis of a wide variety of human diseases . Concerning skin diseases, serum YKL‐40 levels are increased in patients with psoriasis or atopic dermatitis (AD) and correlated with disease severity, suggesting that YKL‐40 is involved in skin inflammatory diseases. However, there have been few reports on YKL‐40 function in skin inflammation.…”

mentioning

confidence: 99%

YKL‐40 augments the proliferation of HaCaT cells via the extracellular regulatory kinase pathway

Suzuki

Miyagaki

Sato

2019

The Journal of Dermatology

View full text Add to dashboard Cite

YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis

Cited by 25 publications

References 6 publications

Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?

Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?

YKL‐40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis

YKL‐40 augments the proliferation of HaCaT cells via the extracellular regulatory kinase pathway

Contact Info

Product

Resources

About